Literature DB >> 22387105

Polypharmacy with common diseases in hospitalized elderly patients.

Fumihiro Mizokami1, Yumiko Koide, Takeshi Noro, Katsunori Furuta.   

Abstract

BACKGROUND: Elderly persons are exposed to polypharmacy because of multiple chronic conditions. Many risk factors for polypharmacy have been identified including age, race/ethnicity, sex, educational achievement level, health status, and number of chronic diseases. However, drugs prescribed for individual diseases have not been analyzed.
OBJECTIVE: The objective of this study was to analyze each common disease in the elderly with respect to prescribed drugs and polypharmacy.
METHODS: A 1-year (January through December 2009) cross-sectional study was performed in which all drugs given to hospitalized elderly patients (age, >65 years) were investigated. Common diseases of the elderly were separated into disease groups including hypertension, hyperlipidemia, gastric ulcer, previous stroke, reflux esophagitis, diabetes mellitus, malignancy, osteoporosis, angina pectoris, congestive heart failure, chronic obstructive pulmonary disease, dementia, and depression.
RESULTS: Among 1768 elderly patients, the mean (range) age of study patients was 78 (65 to 100) years. The mean (SD) number of diseases was 7.7 (3.4), and the number of drugs overall was 4.9 (3.6). The number of drugs and prevalence of polypharmacy were hypertension, 5.2 (3.9 [51%]); hyperlipidemia, 5.6 (3.8 [58%]); gastric ulcer, 5.4 (3.8 [53%]); previous stroke, 5.8 (3.2 [61%]); reflux esophagitis, 5.6 (3.8 [40%]), diabetes mellitus, 5.6 (3.1 [54%]); malignancy, 4.1 (3.1 [37%]); osteoporosis, 5.4 (3.4 [45%]); angina pectoris, 5.7 (3.6 [42%]); congestive heart failure, 6.1 (4.0 [60%]); chronic obstructive pulmonary disease, 5.0 (3.5 [53%]); dementia, 5.1 (3.2 [52%]); and depression, 7.0 (4.2 [73%]).
CONCLUSIONS: When assessing the risk of polypharmacy, physicians should carefully consider the type of any chronic disease. Elderly patients with multiple diseases may be subjected to further polypharmacy.
Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22387105     DOI: 10.1016/j.amjopharm.2012.02.003

Source DB:  PubMed          Journal:  Am J Geriatr Pharmacother        ISSN: 1876-7761


  30 in total

Review 1.  Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis.

Authors:  Tim Johansson; Muna E Abuzahra; Sophie Keller; Eva Mann; Barbara Faller; Christina Sommerauer; Jennifer Höck; Christin Löffler; Anna Köchling; Jochen Schuler; Maria Flamm; Andreas Sönnichsen
Journal:  Br J Clin Pharmacol       Date:  2016-05-07       Impact factor: 4.335

2.  Prevalence and Covariates of Polypharmacy in Elderly Patients on Discharge from a Tertiary 
Care Hospital in Oman.

Authors:  Amna Al-Hashar; Hamed Al Sinawi; Anwar Al Mahrizi; Manal Al-Hatrushi
Journal:  Oman Med J       Date:  2016-11

3.  Polypharmacy and excessive polypharmacy in octogenarians and older acutely hospitalized patients.

Authors:  Christoph Strehblow; Michael Smeikal; Peter Fasching
Journal:  Wien Klin Wochenschr       Date:  2014-01-21       Impact factor: 1.704

4.  Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of Diabetes Mellitus (SUPREME-DM) study.

Authors:  Julie A Schmittdiel; Marsha A Raebel; Wendy Dyer; Stanley Xu; Glenn K Goodrich; Emily B Schroeder; Jodi B Segal; Patrick J O' Connor; Gregory A Nichols; Jean M Lawrence; H Lester Kirchner; Andy J Karter; Jennifer Elston Lafata; Melissa G Butler; John F Steiner
Journal:  J Am Pharm Assoc (2003)       Date:  2014 Jul-Aug

5.  Excessive polypharmacy and survival in polypathological patients.

Authors:  Jesús Díez-Manglano; Mercedes Giménez-López; Vanesa Garcés-Horna; María Sevil-Puras; Elena Castellar-Otín; Paloma González-García; Isabel Fiteni-Mera; Teresa Morlanes-Navarro
Journal:  Eur J Clin Pharmacol       Date:  2015-04-26       Impact factor: 2.953

6.  Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.

Authors:  Dingwei Dai; James A Feinstein; Wynne Morrison; Athena F Zuppa; Chris Feudtner
Journal:  Pediatr Crit Care Med       Date:  2016-05       Impact factor: 3.624

7.  Polypharmacy in the elderly from the clinical toxicologist perspective.

Authors:  H J Heppner; M Christ; M Gosch; W Mühlberg; P Bahrmann; T Bertsch; C Sieber; K Singler
Journal:  Z Gerontol Geriatr       Date:  2012-08       Impact factor: 1.281

8.  Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao.

Authors:  Cheng Kin Lao; Sao Chan Ho; Ka Kit Chan; Chon Fai Tou; Henry Hoi Yee Tong; Alexandre Chan
Journal:  Int J Clin Pharm       Date:  2013-06-28

9.  Impact of Number of Drug Types on Clinical Outcome in Patients with Acute Hip Fracture.

Authors:  H Maki; H Wakabayashi; M Nakamichi; R Momosaki
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

10.  Increasing the Effectiveness of Pharmacotherapy in Psychiatry by Using a Pharmacological Interaction Database.

Authors:  Michal Ordak; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.